Tolerogenic dendritic cells and their application in immunopathological processes
Authors:
A. Grohová 1,2,3; K. Dáňová 1,2; L. Palová-Jelínková 1
Authors place of work:
SOTIO, a. s., Oddělení výzkumu, Praha
1; Ústav imunologie 2. LF UK a FN Motol, Praha
2; Pediatrická klinika 2. LF UK a FN Motol, Praha
3
Published in the journal:
Čes-slov Pediat 2017; 72 (4): 256-262.
Category:
Review
Summary
Tolerogenic dendritic cells (tDC) are specific group of dendritic cells. At steady-state they are located in diverse tissue and play a pivotal role in maintaining central and peripheral immune tolerance. tDC restore and maintain immune homeostasis by inhibition of antigen-specific T-lymphocytes, induction of T-regulatory cells as well as B-regulatory cells and production of anti-inflammatory cytokines. tDC due to their ability to down-regulate immune response are promising tool to re-establish antigen-specific tolerance in autoimmune diseases without adverse effects of systemic immunosuppression. This interventional strategy also offers an interesting way to treat other immunopathological processes.
Key words:
tolerogenic dendritic cells, cellular therapy, immune tolerance, autoimmune disease
Zdroje
1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392 (6673): 245–252.
2. Steinman RM. Dendritic cells: Understanding immunogenicity. Eur J Immunol 2007; 37 (1): 53–60.
3. Doulatov S, Notta F, Eppert K, et al. Revised map of the human progenitor hierarchy shows the origin of macrophages and dendritic cells in early lymphoid development. Nat Immunol 2010; 11 (7): 585–593.
4. Shortman K, Naik SH. Steady-state and inflammatory dendritic-cell development. Nat Rev Immunol 2007; 7 (1): 19–30.
5. Colonna M, Trinchieri G, Liu YJ. Plasmacytoid dendritic cells in immunity. Nat Immunol 2004; 5 (12): 1219–1226.
6. Cools N, Ponsaerts P, Van Tendeloo VF, et al. Balancing between immunity and tolerance: An interplay between dendritic cells, regulatory T cells, and effector T cells. J Leukoc Biol 2007; 82 (6): 1365–1374.
7. Li H, Shi B. Tolerogenic dendritic cells and their applications in transplantation. Cell Mol Immunol 2015; 12 (1): 24–30.
8. Collin M, Mcgovern N, Haniffa M. Human dendritic cell subsets. Immunology 2013; 140 (1): 22–30.
9. Mahnke K, Schmitt E, Bonifaz L, et al. Immature, but not inactive: The tolerogenic function of immature dendritic cells. Immunol Cell Biol 2002; 80 (5): 477–483.
10. Matzinger P. The danger model: A renewed sense of self. Science 2002; 296 (5566): 301–305.
11. Heufler C, Koch F, Stanzl U, et al. Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-gamma production by T helper 1 cells. Eur J Immunol 1996; 26 (3): 659–668.
12. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18: 767–811.
13. Maldonado RA, Von Andrian UH. How tolerogenic dendritic cells induce regulatory T cells. Adv Immunol 2010; 108: 111–165.
14. Sallusto F, Lanzavecchia A. The instructive role of dendritic cells on T-cell responses. Arthritis Res 2002; 4 (3): 127–132.
15. Maggi J, Schafer C, Ubilla-Olguin G, et al. Therapeutic potential of hyporesponsive CD4(+) T cells in autoimmunity. Front Immunol 2015; 6: 488.
16. Stumpfova Z, Hezova R, Meli AC, et al. Microrna profiling of activated and tolerogenic human dendritic cells. Mediators Inflamm 2014; 2014: 259689.
17. Gordon JR, Ma Y, Churchman L, et al. Regulatory dendritic cells for immunotherapy in immunologic diseases. Front Immunol 2014; 5: 7.
18. Lutz MB, Schuler G. Immature, semi-mature and fully mature dendritic cells: Which signals induce tolerance or immunity? Trends Immunol 2002; 23 (9): 445–449.
19. Thompson AG, Thomas R. Induction of immune tolerance by dendritic cells: Implications for preventative and therapeutic immunotherapy of autoimmune disease. Immunol Cell Biol 2002; 80 (6): 509–519.
20. Hubo M, Trinschek B, Kryczanowsky F, et al. Costimulatory molecules on immunogenic versus tolerogenic human dendritic cells. Front Immunol 2013; 4: 82.
21. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192 (7): 1027–1034.
22. Wu J, Horuzsko A. Expression and function of immunoglobulin-like transcripts on tolerogenic dendritic cells. Hum Immunol 2009; 70 (5): 353–356.
23. Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for pd-1 and inhibits t cell activation. Nat Immunol 2001; 2 (3): 261–268.
24. Steinman RM. The control of immunity and tolerance by dendritic cell. Pathol Biol (Paris) 2003; 51 (2): 59–60.
25. Roncarolo MG, Battaglia M. Regulatory t-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat Rev Immunol 2007; 7 (8): 585–598.
26. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003; 21: 685–711.
27. Hwu P, Du MX, Lapointe R, et al. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of t cell prolifera-tion. J Immunol 2000; 164 (7): 3596–3599.
28. Terness P, Bauer TM, Rose L, et al. Inhibition of allogeneic t cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: Mediation of suppression by tryptophan metabolites. J Exp Med 2002; 196 (4): 447–457.
29. Inaba K, Inaba M, Romani N, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992; 176 (6): 1693–1702.
30. Helft J, Bottcher J, Chakravarty P, et al. GM-CSF mouse bone marrow cultures comprise a heterogeneous population of CD11c(+) MHCII(+) macrophages and dendritic cells. Immunity 2015; 42 (6): 1197–1211.
31. Thurner B, Roder C, Dieckmann D, et al. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods 1999; 223 (1): 1–15.
32. Steinman RM, Hemmi H. Dendritic cells: Translating innate to adaptive immunity. Curr Top Microbiol Immunol 2006; 311: 17–58.
33. Yoo S, Ha SJ. Generation of tolerogenic dendritic cells and their therapeutic applications. Immune Netw 2016; 16 (1): 52–60.
34. Naranjo-Gomez M, Raich-Regue D, Onate C, et al. Comparative study of clinical grade human tolerogenic dendritic cells. J Transl Med 2011; 9: 89.
35. Torres-Aguilar H, Sanchez-Torres C, Jara LJ, et al. IL-10/TGF-beta-treated dendritic cells, pulsed with insulin, specifically reduce the response to insulin of CD4+ effector/memory T cells from type 1 diabetic individuals. J Clin Immunol 2010; 30 (5): 659–668.
36. Boks MA, Kager-Groenland JR, Haasjes MS, et al. Il-10-generated tolerogenic dendritic cells are optimal for functional regulatory t cell induction – a comparative study of human clinical-applicable dc. Clin Immunol 2012; 142 (3): 332–342.
37. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor foxp3. Science 2003; 299 (5609): 1057–1061.
38. Svajger U, Obermajer N, Jeras M. IFN-gamma-rich environment programs dendritic cells toward silencing of cytotoxic immune responses. J Leukoc Biol 2014; 95 (1): 33–46.
39. Kerkar SP, Chinnasamy D, Hadi N, et al. Timing and intensity of exposure to interferon-gamma critically determines the function of monocyte-derived dendritic cells. Immunology 2014; 143 (1): 96–108.
40. Harry RA, Anderson AE, Isaacs JD, et al. Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis. Ann Rheum Dis 2010; 69 (11): 2042–2050.
41. Ferreira GB, Van Etten E, Verstuyf A, et al. 1,25-dihydroxyvitamin D3 alters murine dendritic cell behaviour in vitro and in vivo. Diabetes Metab Res Rev 2011; 27 (8): 933–941.
42. Danova K, Klapetkova A, Kayserova J, et al. NF-kappaB, p38 Mapk, Erk1/2, mTor, Stat3 and increased glycolysis regulate stability of paricalcitol/dexamethasone-generated tolerogenic dendritic cells in the inflammatory environment. Oncotarget 2015; 6 (16): 14123–14138.
43. Nikolic T, Roep BO. Regulatory multitasking of tolerogenic dendritic cells - lessons taken from vitamin d3-treated tolerogenic dendritic cells. Front Immunol 2013; 4: 113.
44. Rutella S, Bonanno G, Procoli A, et al. Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features. Blood 2006; 108 (1): 218–227.
45. Watanabe N, Wang YH, Lee HK, et al. Hassall’s corpuscles instruct dendritic cells to induce cd4+cd25+ regulatory t cells in human thymus. Nature 2005; 436 (7054): 1181–1185.
46. Hackstein H, Morelli AE, Larregina AT, et al. Aspirin inhibits in vitro maturation and in vivo immunostimulatory function of murine myeloid dendritic cells. J Immunol 2001; 166 (12): 7053–7062.
47. Mehling A, Grabbe S, Voskort M, et al. Mycophenolate mofetil impairs the maturation and function of murine dendritic cells. J Immunol 2000; 165 (5): 2374–2381.
48. Hackstein H, Taner T, Zahorchak AF, et al. Rapamycin inhibits IL-4–induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood 2003; 101 (11): 4457–4463.
49. Trabanelli S, Lecciso M, Salvestrini V, et al. PGE2-induced IDO1 inhibits the capacity of fully mature DCs to elicit an in vitro antileukemic immune response. J Immunol Res 2015; 2015: 253191.
50. Giannoukakis N. Tolerogenic dendritic cells for type 1 diabetes. Immunotherapy 2013; 5 (6): 569–571.
51. Wang H, Qi F, Dai X, et al. Requirement of B7-H1 in mesenchymal stem cells for immune tolerance to cardiac allografts in combination therapy with rapamycin. Transpl Immunol 2014; 31 (2): 65–74.
52. Jiang XX, Zhang Y, Liu B, et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005; 105 (10): 4120–4126.
53. Giardino G, Gallo V, Prencipe R, et al. Unbalanced immune system: Immunodeficiencies and autoimmunity. Front Pediatr 2016; 4: 107.
54. Miller SD, Turley DM, Podojil JR. Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease. Nat Rev Immunol 2007; 7 (9): 665–677.
55. Hilkens CM, Isaacs JD. Tolerogenic dendritic cell therapy for rheumatoid arthritis: Where are we now? Clin Exp Immunol 2013; 172 (2): 148–157.
56. Hutchinson JA, Geissler EK. Now or never? The case for cell-based immunosuppression in kidney transplantation. Kidney Int 2015; 87 (6): 1116–1124.
57. Danova K, Grohova A, Strnadova P, et al. Tolerogenic dendritic cells from poorly compensated type 1 diabetes patients have decreased ability to induce stable antigen-specific t cell hyporesponsiveness and generation of suppressive regulatory t cells. J Immunol 2017; 198 (2): 729–740.
58. Roep BO, Peakman M. Antigen targets of type 1 diabetes autoimmunity. Cold Spring Harb Perspect Med 2012; 2 (4): 007781.
59. Ten Brinke A, Hilkens CM, Cools N, et al. Clinical use of tolerogenic dendritic cells-harmonization approach in european collaborative effort. Mediators Inflamm 2015; 2015: 471719.
60. Giannoukakis N, Phillips B, Finegold D, et al. Phase Ii (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes Care 2011; 34 (9): 2026–2032.
61. Benham H, Nel HJ, Law SC, et al. Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype-positive rheumatoid arthritis patients. Sci Transl Med 2015; 7 (290): 290–287.
62. Jauregui-Amezaga A, Cabezon R, Ramirez-Morros A, et al. Intraperitoneal administration of autologous tolerogenic dendritic cells for refractory crohn’s disease: A phase I study. J Crohns Colitis 2015; 9 (12): 1071–1078.
63. Bell GM, Anderson AE, Diboll J, et al. Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis. Ann Rheum Dis 2017; 76 (1): 227–234.
64. Joo JB, Chan-Bum CH, Jeongim CH, et al. Phase 1 study of immunotherapy using autoantigen-loaded dendritic cells in patients with anti-citrullinated peptide antigen positive rheumatoid arthritis. http://cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=1645.
Štítky
Neonatology Paediatrics General practitioner for children and adolescentsČlánok vyšiel v časopise
Czech-Slovak Pediatrics
2017 Číslo 4
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
- The Importance of Limosilactobacillus reuteri in Administration to Diabetics with Gingivitis
Najčítanejšie v tomto čísle
- Osteogenesis imperfecta – state of art
-
Infantile hemangiomas.
Current treatment procedures - Hypophosphatasia – skeletal disease requiring our attention
- Tolerogenic dendritic cells and their application in immunopathological processes